Novartis AG (NVS)
Last Price$109.41.9%
Market Cap$217.3B
LTM P/E
18.2x
EPS growth
19.7%
PEGY
0.8x
Peter Lynch Fair Value
$139.2
Undervalued (Peter Lynch formula)
27.3%
Stock quality
7/10
Good
NVS Peter Lynch Fair Value
Crunching data... Almost there!
Best stock ideas on the market right now
With Value Sense, you can find undervalued stocks list with intrinsic value. Discover more stock market investment ideas.
NVS EPS growth & Dividend Yield
Crunching data... Almost there!
NVS vs Peer Set: Peter Lynch Fair Value Comparison
Crunching data... Almost there!
Explore more intrinsic value tools hub for NVS
Margin of safety
Ben Graham Fair Value
Earnings growth model
Discount rate
Peter Lynch charts
Reverse DCF
Earnings Power Value
Intrinsic Value
DCF value calculator
Relative Value
FAQ
What is Novartis AG fair value by Peter Lynch formula?
As of Feb 21, 2025, Novartis AG's fair value using the Peter Lynch formula is $139.2 per share. The current price of $109.4 suggests Novartis AG may be undervalued by this metric.
What is Novartis AG Price to Earnings (P/E) ratio?
As of Feb 21, 2025, Novartis AG's P/E ratio is 18.2x. This is calculated by dividing the current share price of $109.4 by the Earnings per Share (EPS) for the trailing twelve months, which is $5.9. The P/E ratio indicates how much investors are willing to pay for each dollar of earnings.
What is Novartis AG earnings per share (EPS)?
Novartis AG earnings per share (EPS) for the twelve months ending Feb 21, 2025, was $5.9, a 19.7% growth year-over-year.